StockData
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.99+0.04 (+4.57%)

Close on Nov 20, 2026Market cap $13.20MP/E –Yield 0.00%

Tvardi Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Tvardi Therapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$19.35M. For fiscal 2024 it was -$19.35M. The highest annual figure on record is $2.82M in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$19.35M–
FY2023Dec 31, 2023-$94.45M–
FY2022Dec 31, 2022-$78.77M–
FY2021Dec 31, 2021-$60.13M–
FY2020Dec 31, 2020-$5.84M–
FY2019Dec 31, 2019-$109.24M–
FY2018Dec 31, 2018-$22.37M–
FY2017Dec 31, 2017-$54.89M–
FY2016Dec 31, 2016-$48.10M–
FY2015Dec 31, 2015-$21.50M–
FY2014Dec 31, 2014-$17.68M-726.2%
FY2013Dec 31, 2013$2.82M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$4.83M–
Q3 FY2024Sep 30, 2024-$6.66M–
Q2 FY2024Jun 30, 2024$23.43M–
Q1 FY2024Mar 31, 2024-$31.29M–
Q4 FY2023Dec 31, 2023-$19.42M–
Q4 FY2022Dec 31, 2022-$23.51M-128.7%
Q3 FY2022Sep 30, 2022-$25.19M–
Q2 FY2022Jun 30, 2022-$4.50M–
Q1 FY2022Mar 31, 2022-$25.57M–
Q4 FY2020Dec 31, 2020$81.92M–
Q4 FY2019Dec 31, 2019-$31.17M–
Q3 FY2019Sep 30, 2019-$25.64M–
Q2 FY2019Jun 30, 2019-$24.90M-160.7%
Q1 FY2019Mar 31, 2019-$27.54M–
Q4 FY2018Dec 31, 2018-$24.39M–
Q3 FY2018Sep 30, 2018-$20.52M–
Q2 FY2018Jun 30, 2018$41.00M–
Q1 FY2018Mar 31, 2018-$18.47M–
Q4 FY2017Dec 31, 2017-$11.41M–
Q3 FY2017Sep 30, 2017-$9.88M–
Q2 FY2017Jun 30, 2017-$11.95M–
Q1 FY2017Mar 31, 2017-$21.64M–
Q4 FY2016Dec 31, 2016-$13.26M–
Q3 FY2016Sep 30, 2016-$13.39M–

More Tvardi Therapeutics figures

See a number that looks wrong?